ChemoCentryx, Inc. (NASDAQ:CCXI) has scheduled a conference call for 10th August 2020 at 5:00 PM Eastern Time to announce its 2Q20 financial results.
The conference call will also be webcast live under the investor relations section of the website www.chemocentryx.com
Earnings Expectation
ChemoCentryx, Inc. is reporting second quarter financial results on Monday 10th August 2020, after market close.
According to analysts surveyed by Thomson Reuters, CCXI is expected to report 2Q20 loss of $ 0.34 per share from revenue of $ 8.25 million.
For the full year, analysts anticipate top line of $ 35.60 million, while looking forward to loss of $ 1.42 per share bottom line.
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops new medications for inflammatory and autoimmune diseases, and cancer in the United States. The company targets the chemokine and chemoattractant systems to discover, develop, and commercialize orally-administered therapies. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis.
